Tenofovir Amibufenamide Shows Significant Efficacy in Chronic Hepatitis B Patients with Normal ALT Levels
核心洞察
The PROMOTE study, the first large-scale randomized controlled trial in this population, demonstrated that 74.2% of chronic hepatitis B patients with normal ALT (搜索) achieved undetectable viral loads after 48 weeks of tenofovir amibufenamide treatment compared to 9.0% in the control group.
Tenofovir amibufenamide significantly reduced HBV DNA (搜索) levels by 2.63 log10 IU/mL and decreased ALT (搜索) levels by 14.09%, while also reducing the proportion of patients with high-normal ALT levels.
The treatment showed a favorable safety profile with no significant differences in bone, renal, or lipid parameters compared to untreated controls, addressing previous concerns about nucleoside analogue toxicity.
The PROMOTE study has demonstrated significant antiviral efficacy of tenofovir amibufenamide (TMF) in chronic hepatitis B virus (HBV)-infected patients with normal alanine aminotransferase (ALT (搜索)) levels, a population traditionally not considered for treatment under conventional guidelines. The prospective, multicenter, randomized controlled trial enrolled 197 participants and represents the first large-scale investigation of nucleoside analogue therapy in this patient population.
Primary Efficacy Results
At 48 weeks, 74.2% of participants in the TMF group achieved HBV DNA (搜索) levels below 20 IU/mL compared to only 9.0% in the blank control group (P < 0.001). The treatment group demonstrated substantially greater reductions in HBV DNA levels (-2.63 vs. -0.22 log10 IU/mL, P < 0.001) and HBsAg levels (-0.07 vs. -0.04 log10 IU/mL, P = 0.02) compared to untreated controls.
TMF treatment also produced significant improvements in ALT (搜索) levels, with a 14.09% reduction compared to no change in the control group (P = 0.003). Notably, the proportion of patients with high-normal ALT levels (20-40 IU/L) was reduced following treatment, and ALT levels in the TMF group decreased as early as 12 weeks after starting treatment and remained low throughout the study period.
Safety Profile and Disease Progression Risk
The study revealed no significant differences between TMF and blank control groups regarding bone turnover biomarkers, creatinine levels, glomerular filtration rate, lipid profiles, or phosphorus levels. These findings address previous concerns about cumulative toxicity associated with prolonged nucleoside analogue use, particularly regarding skeletal and renal injuries.
Importantly, seven cases in the blank control group experienced ALT (搜索) flares that met disease progression criteria, requiring treatment switch to TMF. These events underscore the risk of disease activity and progression without timely treatment, supporting the necessity of antiviral therapy in chronic HBV-infected patients with normal ALT levels.
Subgroup Analysis and Treatment Considerations
The study identified two subcategories showing less pronounced responses: patients younger than 30 years and those who were HBeAg (搜索)-positive. In HBeAg-positive patients, TMF still significantly reduced viral load compared to controls, particularly evident in patients with baseline HBV DNA (搜索) levels above 2,000 IU/mL. However, the high baseline viral loads in this subgroup made it difficult to achieve levels below 20 IU/mL within the 48-week timeframe.
Clinical Implications for Treatment Guidelines
The results challenge conventional treatment paradigms that have predominantly focused on patients with elevated ALT (搜索) levels. ALT levels do not adequately reflect the degree of liver inflammation or HBV genome integration into hepatocyte DNA, and some patients with normal ALT levels may still benefit from nucleoside analogue treatment.
The study supports expanding antiviral treatment to larger populations, particularly relevant in China, which bears the heaviest global burden of chronic hepatitis B. Early effective treatment may prevent liver inflammation and fibrosis despite normal ALT (搜索) levels and reduce the risk of disease progression to hepatocellular carcinoma.
Ongoing Research and Future Directions
The PROMOTE study continues with planned follow-up assessments at 96 and 144 weeks to evaluate long-term efficacy and safety outcomes. The favorable 48-week safety profile provides a foundation for extended treatment duration, with future results expected to provide more definitive insights into the long-term benefits of treating this patient population.
The research represents a significant step toward a potential "treat-all" strategy for chronic hepatitis B, particularly for HBeAg (搜索)-negative patients with normal ALT (搜索) who typically achieve better treatment outcomes. The study provides high-quality evidence supporting guideline recommendations for antiviral therapy in individuals with normal ALT levels.